SCTX Stock Forecast: Scribe Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$12
−8.70% on the day

The median 12-month analyst price target for Scribe Therapeutics, Inc. is $59. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 10 of 100 as at 21 Nov 2026 — in the weakest quartile.

Market cap
$250.4M
Ticker Nerd rank
10/ 100
Median analyst target
$59
Analysts covering
4
Revenue$1.9M−60.8% y/y
Operating income−$9.4M
Net income−$6.5M
Free cash flow−$5.3M
Quarterly, 4 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−26.2%
1M
−39.1%
From high
−67.6%
From low
0.0%
$12
$37
Range since 24 July 2026, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Scribe Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
10/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
65
Value
39
Issuance
22
Accruals
19
Quality
18
Growth
10
Momentum
6
Volatility
4

Revisions (65): Analysts have, on balance, been raising their forecasts.

Volatility (4): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

SCTX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SCTX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 24 July 2026Adjusted close, US dollars
$10$20$30$40$50$60Aug 26Sep 26Oct 26Nov 26SCTXHigh $60Median $59Low $50

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
4
Buy
0
Hold
0
Sell
$50
Low
$59
Median
$60
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
19 Nov 2026HC Wainwright & Co.ReiteratesBuy$60
3 Sept 2026HC Wainwright & Co.ReiteratesBuy$60
31 Aug 2026HC Wainwright & Co.InitiatesBuy$60
18 Aug 2026GuggenheimInitiatesBuy$50
18 Aug 2026Leerink PartnersInitiatesOutperform$37
18 Aug 2026Wells FargoInitiatesOverweight$60

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for SCTX.

Market Radar

This page is one stock. Monday covers all of them.

SCTX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

SCTX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

SCTX vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120140160Aug 26Sep 26Oct 26Nov 26SCTXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SCTX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
16.9×

Cheaper than 8% of US stocks

Price / book
—
EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
—
Return on assets
−27.9%

Higher than 15% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Scribe Therapeutics, Inc. has a market value of $250.4M and an enterprise value of $81.3M.

  • Shares outstanding: 17.6M.

  • Scribe Therapeutics, Inc. employs 77 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

SCTX and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
SCTXScribe Therapeutics, Inc.$250.4M10
ENTAEnanta Pharmaceuticals, Inc.$221.9M79
PLXProtalix Biotherapeutics, Inc.$233.7M94
IMRXImmuneering Corp.$218.9M48
KROSKeros Therapeutics, Inc.$218.5M83
CAMPCAMP4 Therapeutics Corp.$237.8M49
PYXSPyxis Oncology, Inc.$216.2M74

Take a look at SCTX’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Scribe Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about SCTX

What is the SCTX stock price forecast for 2026-2027?

The median 12-month analyst price target for Scribe Therapeutics, Inc. is $59, with estimates ranging from $50 to $60. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SCTX stock a buy right now?

Of the 4 analysts covering Scribe Therapeutics, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Scribe Therapeutics, Inc. 10 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SCTX?

As at 21 Nov 2026, Scribe Therapeutics, Inc. ranks 10 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (65 of 100).

Will SCTX stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts is $59, and Ticker Nerd's factor model ranks Scribe Therapeutics, Inc. 10 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SCTX stock forecast for 2030?

No analyst covering Scribe Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SCTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $50 to $60 over the next 12 months.

What does Scribe Therapeutics, Inc. do?

Scribe Therapeutics Inc. is a clinical-stage biotechnology company focused on developing in vivo CRISPR-based genetic medicines. Its platform uses custom-engineered enzymes and delivery technologies to create precise therapies designed to address the root causes of disease.

Company

About Scribe Therapeutics, Inc.

Scribe Therapeutics Inc. is a clinical-stage biotechnology company focused on developing in vivo CRISPR-based genetic medicines. Its platform uses custom-engineered enzymes and delivery technologies to create precise therapies designed to address the root causes of disease. The company’s current work centers on cardiometabolic conditions, including cardiovascular and metabolic diseases, with programs aimed at key drivers of atherosclerotic cardiovascular disease. Scribe Therapeutics also advances epigenetic silencing approaches intended to deliver durable therapeutic effects without permanently altering DNA. Based in Alameda, California, Scribe Therapeutics operates at the intersection of gene editing, molecular engineering, and drug development, serving the growing field of genetic medicine with technologies designed for broad clinical use in common diseases.

CEO Dr. Benjamin L. Oakes Ph.D. · 77 employees · United States · https://www.scribetx.com